Array BioPharma
Array BioPharma is a clinical stage publicly traded pharmaceutical company (NASDAQ:ARRY)[1] that is in the NASDAQ Biotechnology Index and is worth over 990 million dollars.[2]
Pipeline
As of 2016, Array BioPharma has a number of compounds in clinical development.[3]
| Drug Name | Stage in Clinical Trials | Development Partner | Indication | Target |
|---|---|---|---|---|
| Binimetinib (MEK162) | Phase 3 | None | Cancer | MEK |
| Encorafenib (LGX818) | Phase 3 | Pierre Fabre | Cancer[4][5] | BRAF |
| Selumetinib | Phase 3 | AstraZeneca | Cancer | MEK |
| Danoprevir | Phase 3 | Roche | Hepatitis C | NS3 |
| Filanesib (ARRY-520) | Phase 2 | None | Multiple myeloma[6] | KSP |
| ARRY-797 | Phase 2 | None | LMNA-related DCM | p38 |
| ARRY-502 | Phase 2 | None | Asthma | CRTh2 |
| Ipatasertib (GDC-0068) | Phase 2 | Genentech | Cancer | AKT |
| Motolimod (VTX2337) | Phase 2 | VentiRX, Celgene | Cancer | TLR |
| Varlitinib (ASLAN001) | Phase 2 | ASLAN | Cancer | Pan-HER |
| LY2606368 | Phase 2 | Eli Lilly | Cancer | CHEK1 |
| LOXO-101 | Phase 2 | Loxo Oncology | Cancer | Pan-TRK |
| ONT-380 | Phase 2 | Oncothyreon | Breast cancer | HER2/neu |
| ARRY-382 | Phase 1 | None | Cancer | CSF1R |
| ARRY-614 | Phase 1 | None | Myelodysplastic syndrome (MDS) | p38/Tie2 |
| GDC-0575 | Phase 1 | Genentech | Cancer | CHEK1 |
| GDC-0994 | Phase 1 | Genentech | Cancer | ERK |
References
- ↑ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ↑ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 1 November 2016.
- ↑ "Product Pipeline".
- ↑ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
- ↑ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
- ↑ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.
This article is issued from Wikipedia - version of the 11/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.